InsiderTrades.com logo
Charles N. York, II net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Charles York, II Biography and Net Worth

Chief Operating and Financial Officer of Day One Biopharmaceuticals

Charles York II, M.B.A. joined Day One in 2021 and brings more than 20 years of corporate finance experience to the Company. In both public and private enterprises in the biotechnology industry, he has held transactional and strategic capital formation roles, including operations, corporate, and business development.

Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development at Aeglea Biotherapeutics, Inc., a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations and corporate development from 2015 – 2021, after joining the company as Vice President, Finance in July 2014. Mr. York has held multiple financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP.  

Mr. York is a CPA in the state of Arizona. He received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.

What is Charles N. York, II's net worth?

The estimated net worth of Charles N. York, II is at least $1.63 million as of February 18th, 2025. Mr. York, II owns 252,638 shares of Day One Biopharmaceuticals stock worth more than $1,629,515 as of May 10th. This net worth estimate does not reflect any other assets that Mr. York, II may own. Learn More about Charles N. York, II's net worth.

How do I contact Charles N. York, II?

The corporate mailing address for Mr. York, II and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at hans@lifesciadvisors.com. Learn More on Charles N. York, II's contact information.

Has Charles N. York, II been buying or selling shares of Day One Biopharmaceuticals?

Charles N. York, II has not been actively trading shares of Day One Biopharmaceuticals during the past quarter. Most recently, Charles N. York II sold 4,370 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a transaction totalling $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company's stock, valued at $3,021,550.48. Learn More on Charles N. York, II's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 19 times. They sold a total of 177,625 shares worth more than $2,563,738.23. The most recent insider tranaction occured on February, 18th when CFO Charles N York II sold 4,370 shares worth more than $52,265.20. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 2/18/2025.

Charles N. York, II Insider Trading History at Day One Biopharmaceuticals

Charles N. York, II Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Charles N York II's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $6.45
Low: $6.35
High: $6.91

50 Day Range

MA: $7.70
Low: $6.30
High: $9.70

2 Week Range

Now: $6.45
Low: $6.26
High: $17.14

Volume

1,335,859 shs

Average Volume

1,077,505 shs

Market Capitalization

$653.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A